318 related articles for article (PubMed ID: 20081105)
1. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.
Nagaraja AK; Creighton CJ; Yu Z; Zhu H; Gunaratne PH; Reid JG; Olokpa E; Itamochi H; Ueno NT; Hawkins SM; Anderson ML; Matzuk MM
Mol Endocrinol; 2010 Feb; 24(2):447-63. PubMed ID: 20081105
[TBL] [Abstract][Full Text] [Related]
2. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
Ma BB; Lui VW; Hui EP; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Chan AT
Invest New Drugs; 2010 Aug; 28(4):413-20. PubMed ID: 19471857
[TBL] [Abstract][Full Text] [Related]
3. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.
Martin EC; Rhodes LV; Elliott S; Krebs AE; Nephew KP; Flemington EK; Collins-Burow BM; Burow ME
Mol Cancer; 2014 Oct; 13():229. PubMed ID: 25283550
[TBL] [Abstract][Full Text] [Related]
4. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
[TBL] [Abstract][Full Text] [Related]
5. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
Mabuchi S; Kawase C; Altomare DA; Morishige K; Sawada K; Hayashi M; Tsujimoto M; Yamoto M; Klein-Szanto AJ; Schilder RJ; Ohmichi M; Testa JR; Kimura T
Clin Cancer Res; 2009 Sep; 15(17):5404-13. PubMed ID: 19690197
[TBL] [Abstract][Full Text] [Related]
6. Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary.
Hisamatsu T; Mabuchi S; Matsumoto Y; Kawano M; Sasano T; Takahashi R; Sawada K; Ito K; Kurachi H; Schilder RJ; Testa JR; Kimura T
Mol Cancer Ther; 2013 Jul; 12(7):1367-77. PubMed ID: 23615631
[TBL] [Abstract][Full Text] [Related]
7. HULC functions as an oncogene in ovarian carcinoma cells by negatively modulating miR-125a-3p.
Chu P; Xu L; Su H
J Physiol Biochem; 2019 Jun; 75(2):163-171. PubMed ID: 30863948
[TBL] [Abstract][Full Text] [Related]
8. MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway.
Dai C; Xie Y; Zhuang X; Yuan Z
Biomed Pharmacother; 2018 Aug; 104():763-770. PubMed ID: 29807226
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-181 Functions as an Antioncogene and Mediates NF-κB Pathway by Targeting RTKN2 in Ovarian Cancers.
Lin Z; Li D; Cheng W; Wu J; Wang K; Hu Y
Reprod Sci; 2019 Aug; 26(8):1071-1081. PubMed ID: 30309296
[TBL] [Abstract][Full Text] [Related]
11. The lncRNA SNHG15/miR-18a-5p axis promotes cell proliferation in ovarian cancer through activating Akt/mTOR signaling pathway.
Zhang J; Wang L; Jiang J; Qiao Z
J Cell Biochem; 2020 Dec; 121(12):4699-4710. PubMed ID: 33135285
[TBL] [Abstract][Full Text] [Related]
12. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors.
Doghman M; El Wakil A; Cardinaud B; Thomas E; Wang J; Zhao W; Peralta-Del Valle MH; Figueiredo BC; Zambetti GP; Lalli E
Cancer Res; 2010 Jun; 70(11):4666-75. PubMed ID: 20484036
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
[TBL] [Abstract][Full Text] [Related]
14. miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1.
Deng H; Qianqian G; Ting J; Aimin Y
Biomed Pharmacother; 2018 Oct; 106():1072-1081. PubMed ID: 30119173
[TBL] [Abstract][Full Text] [Related]
15. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
Mabuchi S; Altomare DA; Connolly DC; Klein-Szanto A; Litwin S; Hoelzle MK; Hensley HH; Hamilton TC; Testa JR
Cancer Res; 2007 Mar; 67(6):2408-13. PubMed ID: 17363557
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
[TBL] [Abstract][Full Text] [Related]
17. Suppression of SIK1 by miR-141 in human ovarian cancer cell lines and tissues.
Chen JL; Chen F; Zhang TT; Liu NF
Int J Mol Med; 2016 Jun; 37(6):1601-10. PubMed ID: 27081781
[TBL] [Abstract][Full Text] [Related]
18. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
[TBL] [Abstract][Full Text] [Related]
19. miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway.
Riquelme I; Tapia O; Leal P; Sandoval A; Varga MG; Letelier P; Buchegger K; Bizama C; Espinoza JA; Peek RM; Araya JC; Roa JC
Cell Oncol (Dordr); 2016 Feb; 39(1):23-33. PubMed ID: 26458815
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L
Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]